Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and ...

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...

The global proteinase K market is projected to grow from US$ 27.5 million in 2023 to US$ 43.9 million by 2033, at a CAGR of 4 ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Increases speed to market for drug developers working on nucleic acid therapeutics.

The Company also announced that it plans to announce its fourth quarter and full year 2024 financial and operating results after the market closes on Tuesday, February 25, 2025, and will host a ...

Human Metapneumovirus (HMPV) primarily spreads through respiratory secretions from coughing or sneezing, close personal ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.TRc4SPmX.js ...

Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm's expertise in customized nucleic ...